Caxton Associates LP Viking Therapeutics, Inc. Transaction History

Caxton Associates LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.72 - $9.4 $433,597 - $1.5 Million	-159,411 Reduced 79.3%	41,622 $391,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $236,168 - $360,272	-92,615 Reduced 31.54%	201,033 $547,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $415,621 - $620,477	196,977 Added 203.76%	293,648 $849,000
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $234,495 - $381,445	78,165 Added 422.38%	96,671 $290,000
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $74,777 - $94,343	-13,401 Reduced 42.0%	18,506 $116,000
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $35,515 - $46,053	-6,843 Reduced 17.66%	31,907 $191,000
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $108,193 - $182,269	18,849 Added 94.71%	38,750 $245,000
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $105,475 - $133,535	19,901 New	19,901 $112,000

476

63.4M

5.76M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.5B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.